logo
Plus   Neg
Share
Email

GM Defense Begins Facility Renovation To Support Infantry Squad Vehicle Production

GM Defense LLC, a subsidiary of automaker General Motors Co. (GM), said Thursday it has started renovations of an existing GM building to support the production of the Infantry Squad Vehicle or ISV.

The ISV is a light and agile all-terrain troop carrier intended to transport a nine-Soldier infantry squad. The ISV is based off the 2020 Chevrolet Colorado ZR2 midsize truck architecture.

The ISV program is the first major award for GM Defense since the subsidiary was re-established by its parent company in 2017.

The existing GM facility, located in Concord, North Carolina, will produce ISVs for the U.S. Army as part of a $214.3 million contract awarded to GM Defense in June 2020. GM Defense delivered its first ISVs to the U.S. Army in October this year, just 120 days from contract award.

GM Defense expects construction at the 75,000-square-foot facility to continue into early spring. The production line will begin delivering vehicles in April.

As GM Defense ramps to full-rate production, the facility will help to manufacture 649 ISVs and will support the production of up to 2,065 vehicles with additional authorization over eight years.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mediterranean Food Inc is recalling its "Alqosh Sesame Oil" citing the potential to be contaminated with Salmonella, the U.S. Food and Drug Administration said. The affected Alqosh Sesame Oil "Tahin" comes in a 2Lb, clear plastic jar marked with lot # 16082020 on the side of the jar and with a Production date of 08/16/2020 stamped on the side. Twitter has filed a lawsuit against Texas Attorney General Ken Paxton, seeking to halt his ongoing investigation into the company's content moderation practices. Paxton, a Republican and supporter of former president Donald Trump, on January 13 had sent a civil investigative demand or CID to Twitter after its decision to permanently suspend Trump from the social media platform... The U.S. Food and Drug Administration granted emergency use authorization (EUA) for the first and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19. The test confirms recent or prior COVID-19 infection. Developed by Adaptive Biotechnologies, T-Detect COVID Test is a next generation sequencing based (NGS) test.
Follow RTT